Andy Haigh, the President and CEO of Adapsyn Bioscience, joins the "Conversations" podcast to talk about antimicrobial resistance. A Hamilton-based chemical bioinformatics company, Adapsyn is a world leader in the discovery and development of novel bacterial metabolites for use as therapeutics.
"OUR VISION IS TO DISCOVER AND DEVELOP MEANINGFUL SOLUTIONS THAT WILL ELIMINATE THE THREAT OF ANTIMICROBIAL RESISTANCE ACROSS THE GLOBE."
"OUR VISION IS TO DISCOVER AND DEVELOP MEANINGFUL SOLUTIONS THAT WILL ELIMINATE THE THREAT OF ANTIMICROBIAL RESISTANCE ACROSS THE GLOBE."
"OUR VISION IS TO DISCOVER AND DEVELOP MEANINGFUL SOLUTIONS THAT WILL ELIMINATE THE THREAT OF ANTIMICROBIAL RESISTANCE ACROSS THE GLOBE."
